After the EMA recognized a “possible link” between vaccination with AstraZeneca and “very rare cases of blood clots”, especially in young people, several countries announced to limit its use to people beyond a certain age.
Belgium decided on April 7 to reserve the use of the AstraZeneca vaccine for people over 55, following in particular the opinion of the European Medicines Agency (EMA) confirming a “possible link [avec] very rare cases of blood clots ”. The EMA had however specified that the risk / benefit balance remained positive.
“On the basis of recent scientific advice, the Belgian health ministers have decided to replace [le vaccin] AstraZeneca with other vaccines for people aged 18 to 55; for people 56 years of age and over, all vaccines will continue to be given, ”health officials said in a statement.
“The Pharmacovigilance Committee (PRAC) and EMA draw attention to reports of very rare side effects (combination of reduced platelet count and severe thrombosis) up to 14 days after administration of AstraZeneca vaccine (AZ), especially in young people, especially in Germany, France and the United Kingdom, “continued the statement, which specifies that it is” 100 cases out of more than 25 million people vaccinated “.
“From the age of 56, vaccination significantly reduces the risk of hospitalization and death, while the expected side effects remain extremely rare”, underline the Belgian health authorities.
Also reacting to the EMA press release, Spain announced the same day to reserve AstraZeneca’s anti-Covid vaccine for people over 60 for the same reasons.
Italy also made a similar announcement on April 7, explaining that it had been decided “to recommend the use preferably [du vaccin d’AstraZeneca] to people aged over 60 ”.
Other countries had already taken similar measures. France reserves the vaccine for people aged 55 and over, Germany and the Netherlands for those over 60.